Compare FCUV & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCUV | DRMA |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.9M |
| IPO Year | 2013 | N/A |
| Metric | FCUV | DRMA |
|---|---|---|
| Price | $1.46 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.7M | 71.5K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $255,023.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $650.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.59 |
| 52 Week High | $12.83 | $7.33 |
| Indicator | FCUV | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 35.72 | 41.81 |
| Support Level | $0.63 | $1.13 |
| Resistance Level | $2.44 | $1.40 |
| Average True Range (ATR) | 0.44 | 0.09 |
| MACD | -0.11 | -0.00 |
| Stochastic Oscillator | 3.29 | 0.43 |
Focus Universal Inc focuses on commercializing universal smart technology and financial reporting software. It plans to utilize its universal smart technology for smart meters and automation systems, which will be incorporated into IoT devices. The company has developed the five proprietary platform technologies: device on a chip; universal smart instrumentation platform (USIP); 5G ultra-narrowband technology; ultra-narrowband power line communication (PLC) technology; and its financial reporting software. The company consists of two segments: LED and IoT Installation Services, and SEC Financial Software segment. It derives the majority of the revenue from LED and IoT Installation Services segment which handles LED and IoT installation and management business.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.